Ellyn L. Peterson
Sarepta Therapeutics (United States)(US)
Publications by Year
Research Areas
Muscle Physiology and Disorders, Virus-based gene therapy research, Viral Infections and Immunology Research, Cardiomyopathy and Myosin Studies, CAR-T cell therapy research
Most-Cited Works
- → Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy(2017)85 cited
- → Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy(2021)83 cited
- → Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion(2019)45 cited
- → Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74(2024)26 cited
- → Preclinical Systemic Delivery of Adeno-Associated α-Sarcoglycan Gene Transfer for Limb-Girdle Muscular Dystrophy(2020)22 cited
- → Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse model(2023)18 cited
- → An Isolated Limb Infusion Method Allows for Broad Distribution of rAAVrh74.MCK.GALGT2 to Leg Skeletal Muscles in the Rhesus Macaque(2018)15 cited
- → LIMB GIRDLE MUSCULAR DYSTROPHIES(2020)4 cited
- → Eteplirsen, a phosphorodiamidate morpholino oligomer (PMO) for Duchenne muscular dystrophy (DMD): Longitudinal comparison to external controls on six-minute walk test (6MWT) and loss of ambulation (LOA)(2016)2 cited
- → Quantification of dystrophin to assess the effects of dystrophin-restoring treatments in Duchenne muscular dystrophy: Lessons from the development of eteplirsen(2017)2 cited